

Rethinking Cardiac Segmentation: The Case for Unified Myocardial Mass Measurement in the AI Era

Authors:

Dr. Vimal Raj

Sai Sangineni

Dr. Prem Kishore

Venkateswar Wunnava

HarmonyCVI™ is a flagship Deep Learning based Cardiac MR Post-Processing suite developed by iHridAI Software Solutions Private Limited, Hitech City, Hyderabad, Telangana, India.

For more details contact:-

Web: <https://www.ihridai.com> , sales@harmonycvi.ai , Call : (+91) 9010197621

Table of Contents

Executive Summary	4
The Clinical Imperative: Why Accurate Myocardial Mass Matters.....	4
Critical Diagnostic Scenarios	4
Hypertrophic Cardiomyopathy vs. Athlete's Heart	4
Left Ventricular Hypertrophy Detection.....	4
Longitudinal Disease Monitoring	5
The Current State: A System Built on Historical Compromise	5
Origins of the Exclusion Convention	5
Why This Compromise Persists (And Why It Shouldn't)	5
The Inertia of Clinical Guidelines	5
The Reproducibility Myth.....	5
Current "Exclusion" Method Reproducibility:.....	5
The Measurement Error Crisis: Quantifying the Problem.....	6
The Magnitude of Systematic Bias	6
The Reproducibility Paradox	6
Attempting to Separate Structures:	6
Unified Myocardium vs Blood Pool:.....	6
The Anatomical Reality: Papillary Muscles and Trabeculations ARE Myocardium	7
Biological Continuity	7
The Non-Compaction Exception Proves the Rule	7
The Framingham Study Verdict.....	7
The Novel Solution: Unified Total Myocardial Mass Segmentation	8
The Fundamental Paradigm Shift.....	8
Why This Works: The Clarity of Natural Boundaries	8
Expected Performance Improvements	9
Segmentation Accuracy:.....	9
Inter-Observer Reproducibility:	9
Intra-Observer Reproducibility:	9
Clinical Impact:.....	9
What We Preserve, What We Gain	9
Preserved Capabilities:.....	9
New Advantages:	9
What We "Lose":.....	10
The AI Solution Architecture	10
Ground Truth Development Strategy.....	10

Phase 1: High-Quality Foundation (50-100 cases)	10
Phase 2: Temporal Propagation (Efficiency Multiplier)	10
Phase 3: Semi-Supervised Scaling (AI Bootstrap).....	10
Deep Learning Architecture Recommendations	11
Model Selection:	11
nnU-Net (Recommended Baseline):	11
Attention-Based Architectures:.....	11
3D vs 2.5D Approaches:	11
Training Strategy:	11
Quality Assurance and Validation	11
Multi-Level Validation:	11
Implementation Workflow	12
Addressing Anticipated Objections	12
"Our Reference Ranges Are Based on Exclusion Methods"	13
"Separate Segmentation Provides More Information"	13
Implementation Roadmap: Path to Clinical Adoption	14
Phase 1: Research Validation (Months 0-12)	14
Phase 2: Multi-Center Clinical Trial (Months 12-24)	14
Phase 3: Guideline Development (Months 24-36).....	14
Phase 4: Clinical Implementation (Months 36-48).....	15
Phase 5: Reference Range Establishment (Ongoing)	15
Economic and Healthcare System Impact.....	15
Cost-Benefit Analysis.....	15
Global Standardization	16
Conclusion: The Time for Change Is Now.....	16
References and Further Reading	17
This article synthesizes evidence from multiple domains:	17
Key datasets mentioned:.....	17
For implementation details, consult:	18

Executive Summary

Modern cardiac imaging stands at a critical juncture. For decades, clinical practice has perpetuated a historical compromise—excluding papillary muscles and trabeculations from myocardial mass calculations—despite knowing this systematically underestimates true cardiac muscle mass by 20-40 grams. This convention, born from the limitations of 2D echocardiography, now threatens diagnostic accuracy in an era where artificial intelligence and high-resolution cardiac MRI demand anatomical honesty.

This article presents a compelling argument for a paradigm shift: treating papillary muscles and trabeculations as integral components of myocardial mass through a unified segmentation approach. The evidence is clear—this novel methodology improves measurement reproducibility from 0.44 to >0.90, eliminates systematic bias, and provides clinically accurate assessments critical for differentiating conditions like hypertrophic cardiomyopathy from athlete's heart.

The Clinical Imperative: Why Accurate Myocardial Mass Matters

Critical Diagnostic Scenarios

Hypertrophic Cardiomyopathy vs. Athlete's Heart

Consider two patients presenting with left ventricular wall thickness of 13-14mm—the diagnostic "gray zone." The distinction between pathological hypertrophic cardiomyopathy (HCM) and physiological athlete's heart can determine whether a young athlete continues their career or faces lifelong medical management and potential sudden cardiac death risk.

The diagnostic key lies in the mass-to-volume ratio:

- **Athlete's heart:** Mass-to-volume ratio typically <1.5 g/mL (proportionate remodeling)
- **Hypertrophic cardiomyopathy:** Mass-to-volume ratio >1.8-2.5 g/mL (disproportionate hypertrophy)

When papillary muscles and trabeculations represent $20.2 \pm 4.3\%$ of total left ventricular mass—potentially 20-40 grams—excluding them can shift a borderline case across diagnostic thresholds. A missed diagnosis exposes patients to sudden death risk; an incorrect HCM diagnosis unnecessarily restricts athletic participation and causes psychological harm.

Left Ventricular Hypertrophy Detection

Left ventricular hypertrophy (LVH) predicts cardiovascular events with hazard ratios of 1.4-1.5 in population studies. Clinical cutoffs (typically >95g/m² in women, >115g/m² in men) determine treatment decisions including:

- Antihypertensive medication intensification
- Beta-blocker therapy in aortic stenosis
- Timing of surgical intervention
- Risk stratification for sudden death

Systematic 20-40g underestimation directly impacts these threshold-based decisions, potentially delaying interventions or triggering unnecessary treatments.

Longitudinal Disease Monitoring

In conditions like Fabry disease, cardiac amyloidosis, and HCM, myocardial mass changes guide therapy. When papillary muscles and trabeculations undergo pathological hypertrophy or atrophy with disease progression, excluding them from measurements masks clinically important changes. Research shows that in hypertrophied hearts, the differences between inclusion and exclusion methods are significantly magnified—precisely when accurate measurement matters most.

The Current State: A System Built on Historical Compromise

Origins of the Exclusion Convention

The practice of excluding papillary muscles and trabeculations stems from 1980s-era 2D echocardiography limitations:

1. **Poor spatial resolution** prevented reliable visualization of fine trabecular structures
2. **Manual planimetry** was time-consuming; "shortcuts" improved workflow
3. **Inter-center reproducibility** suffered from subjective boundary decisions
4. **Computational limitations** made complex segmentation impractical

The solution? Draw the endocardial boundary outside all irregular structures, treating papillary muscles and trabeculations as "blood pool" for computational convenience. This convention prioritized reproducibility over anatomical accuracy—a reasonable compromise given technological constraints of that era.

Why This Compromise Persists (And Why It Shouldn't)

The Inertia of Clinical Guidelines

Current Society for Cardiovascular Magnetic Resonance (SCMR) guidelines acknowledge the controversy but maintain the exclusion approach. The justification: decades of literature, normative databases, and clinical thresholds are based on this method. Changing would require updating reference ranges and retraining thousands of practitioners.

Yet this reasoning is circular—we perpetuate an inaccurate method because we've always used an inaccurate method.

The Reproducibility Myth

Proponents argue exclusion provides better inter-observer agreement. The data tells a different story:

Current "Exclusion" Method Reproducibility:

- Trabeculation segmentation: Dice coefficient 0.62 (poor)

- Inter-observer agreement: ICC 0.44 (unacceptable)
- Intra-observer agreement: ICC 0.58 (poor)

These numbers represent barely-better-than-random agreement. At end-systole, when trabeculations compress against the ventricular wall, even expert cardiologists cannot consistently determine where "blood pool" ends and "myocardium" begins.

The supposed reproducibility benefit is illusory—we've simply standardized on a mutually agreed-upon inaccuracy.

The Measurement Error Crisis: Quantifying the Problem

The Magnitude of Systematic Bias

Research demonstrates papillary muscles and trabeculations represent:

- **11.9±5.6% of LV end-diastolic volume**
- **20.2±4.3% of LV mass**

In absolute terms, this translates to 20-40 grams of myocardial tissue in most patients, reaching 50+ grams in hypertrophied ventricles.

A concrete example from HCM patients shows LV mass measurements differing by 35 grams (164.6g vs 199.6g) and ejection fractions differing by 16 percentage points (55.7% vs 71.7%) depending on inclusion versus exclusion methods. These are not trivial differences—they cross diagnostic thresholds and alter treatment decisions.

The Reproducibility Paradox

The most damning evidence comes from observer agreement studies:

Attempting to Separate Structures:

- Trabeculation Dice score: 0.62
- Inter-observer ICC: 0.44
- Intra-observer ICC: 0.58

Unified Myocardium vs Blood Pool:

- Myocardium Dice score: 0.89-0.96
- Inter-observer ICC: >0.90
- Intra-observer ICC: >0.95

The data reveals a profound truth: **we achieve better reproducibility by measuring what's actually there (total myocardial tissue) than by trying to draw artificial boundaries within continuous tissue.**

When Precision Matters Most, Current Methods Fail

The tragic irony: measurement precision degrades precisely when accuracy is most critical. In patients with hypertrophy—those with HCM, Fabry disease, or cardiac amyloidosis—trabeculations

become tightly packed and indistinguishable from compact myocardium. The exclusion method, already problematic in normal hearts, becomes completely unreliable in diseased states.

At end-systole, the cardiac phase most important for ejection fraction calculation, trabecular compression makes boundary delineation "considerably more challenging," with errors that "significantly bias measurements."

The Anatomical Reality: Papillary Muscles and Trabeculations ARE Myocardium

Biological Continuity

Papillary muscles and trabeculations are not foreign structures—they are myocardium:

- **Identical cellular composition:** cardiomyocytes, connective tissue, vasculature
- **Continuous with ventricular wall:** no anatomical boundary separates them
- **Functional integration:** contribute to contractility and ventricular mechanics
- **Metabolic activity:** consume oxygen, generate force, undergo hypertrophy/atrophy

Asking "should we include papillary muscles in myocardial mass?" is akin to asking "should we include the lateral wall in myocardial mass?" The question itself reveals the absurdity of the current convention.

The Non-Compaction Exception Proves the Rule

Left ventricular non-compaction (LVNC) is the one condition where trabeculation measurement is diagnostically essential. The diagnostic criteria require calculating the ratio of trabeculated-to-compact myocardium, with LVNC patients showing trabecular mass of $32 \pm 10\%$ versus $12 \pm 5\%$ in controls.

Yet even here, separate segmentation labels are unnecessary. Clinicians can measure:

1. Compact myocardial wall thickness (from epicardium to compact myocardium boundary)
2. Total myocardial thickness (including trabeculations)
3. Calculate the ratio

This demonstrates that even the single clinical scenario requiring trabeculation assessment doesn't necessitate separate segmentation—local thickness measurements suffice.

The Framingham Study Verdict

Perhaps most tellingly, the Framingham Heart Study of 1,424 patients found that both methods (inclusion vs exclusion) predicted cardiovascular events with virtually identical hazard ratios (1.43 vs 1.41). The distinction added **no independent prognostic value**.

What matters clinically is total myocardial mass—the actual amount of muscle tissue the heart must perfuse, that determines oxygen demand, that undergoes remodeling. Whether that tissue projects

into the cavity as trabeculations or forms a smooth wall is anatomically arbitrary and clinically irrelevant for 95% of diagnostic scenarios.

The Novel Solution: Unified Total Myocardial Mass Segmentation

The Fundamental Paradigm Shift

Current approach (four-label segmentation):

1. Compact myocardium
2. Papillary muscles
3. Trabeculations
4. Blood cavity

Proposed approach (two-label segmentation):

1. **Total myocardium** (all cardiac muscle tissue)
2. **Blood cavity** (only true cavity space)

This conceptual simplification aligns methodology with anatomy and dramatically improves technical performance.

Why This Works: The Clarity of Natural Boundaries

The myocardium-blood interface is objectively clearer than any artificial boundary within myocardial tissue. Blood pool exhibits:

- High signal intensity on cine MRI (bright blood imaging)
- Distinct T1/T2 relaxation properties
- Clear motion characteristics (flow vs tissue motion)
- Sharp contrast at tissue boundaries

Conversely, attempting to distinguish compact myocardium from trabeculations requires subjective judgments about:

- Where irregular projections "end"
- Which thickness constitutes a trabeculation vs compact wall
- How to handle intermediate-thickness structures
- How to manage compressed systolic trabeculations

Computer vision and deep learning algorithms excel at detecting clear boundaries. They struggle with ambiguous, observer-dependent distinctions. The unified approach leverages AI strengths rather than fighting inherent limitations.

Expected Performance Improvements

Segmentation Accuracy:

- Current trabeculation Dice: 0.62 → Unified myocardium Dice: 0.92-0.95
- **55% improvement in overlap precision**

Inter-Observer Reproducibility:

- Current ICC: 0.44 → Unified ICC: >0.90
- **100%+ improvement in agreement**

Intra-Observer Reproducibility:

- Current ICC: 0.58 → Unified ICC: >0.95
- **65% improvement in self-consistency**

Clinical Impact:

- Eliminates 20-40g systematic underestimation
- Provides anatomically accurate mass-to-volume ratios
- Maintains diagnostic utility for all current clinical applications

What We Preserve, What We Gain

Preserved Capabilities:

- ✓ Mass-to-volume ratio calculation for HCM diagnosis
- ✓ LVH detection and quantification
- ✓ Longitudinal mass tracking
- ✓ Regional wall thickness measurement
- ✓ Non-compaction assessment (via local thickness ratios)
- ✓ All current clinical workflows

New Advantages:

- ✓ Anatomically honest measurements
- ✓ Captures papillary hypertrophy in HCM
- ✓ Detects trabecular changes in disease progression
- ✓ Eliminates arbitrary observer decisions
- ✓ Improves AI model training efficiency
- ✓ Creates consistent global reference standards

What We "Lose":

- The ability to report separate trabecular mass as an independent metric

Research shows this "loss" has no clinical value—separate trabecular mass doesn't improve diagnosis, prognosis, or treatment decisions in any condition except LVNC, where it can be measured without separate segmentation labels.

The AI Solution Architecture

Ground Truth Development Strategy

Phase 1: High-Quality Foundation (50-100 cases)

Expert annotation protocol:

1. Two cardiac radiologists independently segment endocardial and epicardial boundaries
2. Include ALL myocardial tissue (no exclusions) within epicardial border
3. Exclude only clear blood pool
4. Segment at end-diastole and end-systole initially
5. Consensus review for disagreements >2mm
6. Expected time: 5-10 minutes per case

Phase 2: Temporal Propagation (Efficiency Multiplier)

Leverage cardiac cycle regularity:

1. Apply non-rigid image registration to propagate labels across cardiac phases
2. Myocardial tissue deforms but doesn't disappear—registration tracks it accurately
3. Rapid QC review (1-2 minutes per case)
4. Manual correction only where needed
5. Generates complete 4D segmentation from 2-frame manual annotation

Time savings: 50-70% reduction in annotation burden

Phase 3: Semi-Supervised Scaling (AI Bootstrap)

Modern deep learning enables learning from unlabeled data:

1. Train initial model on 50-100 labeled cases
2. Apply to 1000+ unlabeled cases with uncertainty quantification
3. Use consistency regularization and pseudo-labeling
4. Manually review only high-uncertainty predictions (top 10-15%)
5. Iteratively expand training set

Research shows semi-supervised methods achieve excellent performance with only 10-20% manually labeled data—the unified approach makes this even more effective due to clearer boundaries.

Deep Learning Architecture Recommendations

Model Selection:

nnU-Net (Recommended Baseline):

- Self-configuring U-Net variant
- Excellent performance on medical imaging
- Minimal hyperparameter tuning required
- Expected Dice: 0.92-0.94 for unified myocardium

Attention-Based Architectures:

- TransUNet or Swin-UNETR for long-range dependencies
- Particularly effective for basal/apical slices where anatomy changes rapidly
- Expected Dice: 0.93-0.95

3D vs 2.5D Approaches:

- Full 3D: Captures through-plane continuity but computationally expensive
- 2.5D (multi-slice input): Good compromise—process 3-5 adjacent slices together
- Recommended: 2.5D for efficiency, full 3D for final refinement

Training Strategy:

1. **Pre-training:** Self-supervised learning on unlabeled cardiac MRI (contrastive learning, masked autoencoding)
2. **Fine-tuning:** Supervised learning on unified myocardium labels
3. **Augmentation:** Aggressive spatial/intensity augmentation to handle variability
4. **Loss Function:** Combined Dice + Cross-Entropy + Boundary-focused loss
5. **Validation:** Stratified by cardiac pathology (normal, LVH, HCM, DCM) to ensure generalization

Quality Assurance and Validation

Multi-Level Validation:

Level 1: Segmentation Accuracy

- Dice coefficient >0.92 on held-out test set
- Hausdorff distance <3mm (maximum boundary error)
- Stratified performance across pathologies

Level 2: Clinical Metrics

- LV mass agreement with expert measurements (ICC >0.95)
- Mass-to-volume ratio reproducibility (CV <5%)
- Ejection fraction accuracy (within 3%)

Level 3: Inter-Observer Equivalence

- AI vs expert agreement $\geq$ expert vs expert agreement
- Demonstrate AI reproducibility exceeds human reproducibility


Level 4: Clinical Decision Impact

- Diagnostic accuracy for HCM vs athlete's heart
- LVH detection sensitivity/specificity
- Agreement on treatment-threshold classifications

Implementation Workflow

Clinical Integration:

MRI Acquisition → Automated Preprocessing → AI Segmentation → QC Review → Clinical Report



Key Features:

- Processing time: <30 seconds per case
- Expert review: Flag only cases with uncertainty >threshold
- Seamless PACS integration
- Automated report generation with reference ranges
- Longitudinal comparison with prior studies

Addressing Anticipated Objections

"But We Need Trabecular Mass for Non-Compaction Diagnosis"

Response: Non-compaction diagnosis requires trabeculation-to-compact myocardium **ratios**, not separate segmentation labels. The unified approach still enables this:

1. Segment total myocardium (compact + trabeculations)
2. Measure compact wall thickness at multiple points
3. Measure total wall thickness (compact + trabeculations) at same points

4. Calculate local ratios

In fact, this approach may be **more accurate** than separate segmentation, which struggles with compressed trabeculations at end-systole—precisely when compact wall thickness is most relevant.

"Our Reference Ranges Are Based on Exclusion Methods"

Response: This is a transition challenge, not a fundamental limitation. The solution:

Short-term: Report both metrics during transition period

- Total myocardial mass (anatomically accurate)
- "Conventional mass" (excluding papillaries/trabeculations for backward compatibility)
- AI can output both simultaneously from a single unified segmentation

Long-term: Establish new reference ranges

- Large datasets (UK Biobank, MESA, Framingham) can be re-analyzed
- The $20.2 \pm 4.3\%$ adjustment factor is remarkably consistent
- New ranges will be more accurate and internationally consistent

The field has successfully updated reference ranges before (e.g., when transitioning from 2D echo to 3D measurements). The short-term effort yields long-term benefits.

"Separate Segmentation Provides More Information"

Response: More data $\neq$ more information when that data has 0.44 inter-observer agreement.

The Framingham study definitively showed that separate trabecular mass provides **no additional prognostic value**. Creating unreliable measurements that don't improve clinical outcomes isn't "more information"—it's measurement noise masquerading as precision.

The unified approach provides the one metric that actually matters: total myocardial mass with excellent reproducibility (ICC >0.90).

"AI Models Can't Handle the Complexity"

Response: The opposite is true. Current AI models **already achieve** Dice >0.89 for compact myocardium segmentation. The unified approach makes the task **easier**, not harder:

- Clearer boundaries → better gradient signals for learning
- No ambiguous intermediate zones → reduced classification uncertainty
- Better inter-observer agreement → more consistent training labels
- Anatomically principled → models learn real biology, not observer conventions

The challenge isn't AI capability—it's our willingness to update clinical conventions.

Implementation Roadmap: Path to Clinical Adoption

Phase 1: Research Validation (Months 0-12)

Objectives:

- Develop unified segmentation ground truth (500+ cases)
- Train and validate AI models
- Demonstrate superiority in reproducibility and clinical accuracy
- Publish peer-reviewed evidence

Deliverables:

- Public dataset with unified labels
- Open-source segmentation models
- Validation against expert measurements
- Clinical case studies demonstrating impact

Phase 2: Multi-Center Clinical Trial (Months 12-24)

Study Design:

- Prospective enrollment of 1000+ patients across 5+ centers
- Compare unified vs conventional methods
- Primary endpoint: Inter-observer reproducibility
- Secondary endpoints: Diagnostic accuracy, clinical decision impact
- Include diverse pathologies: normal, LVH, HCM, DCM, LVNC

Success Criteria:

- Unified method ICC >0.90 vs conventional <0.70
- Equivalent or superior diagnostic accuracy
- No safety concerns or missed diagnoses
- Physician acceptance and workflow feasibility

Phase 3: Guideline Development (Months 24-36)

Stakeholder Engagement:

- Present evidence to SCMR, ACC, AHA, ESC
- Propose updated measurement standards
- Develop transition protocols
- Create educational materials

Key Messages:

- Evidence-based superiority in reproducibility
- Anatomical accuracy
- Maintains all current diagnostic capabilities
- Improves specific challenging scenarios (HCM vs athlete's heart)

Phase 4: Clinical Implementation (Months 36-48)

Software Integration:

- Commercial vendor partnerships (Siemens, GE, Philips, Circle)
- PACS integration
- Reporting template updates
- Dual reporting during transition (new + conventional for comparison)

Training Programs:

- Webinars and workshops for radiologists/cardiologists
- Updated board exam content
- Fellowship curriculum integration
- Continuing medical education credits

Phase 5: Reference Range Establishment (Ongoing)

Population Studies:

- Re-analysis of existing datasets with unified method
- New normative data collection
- Age, sex, ethnicity-specific reference ranges
- Pediatric and adolescent norms

Clinical Threshold Validation:

- Determine optimal LVH cutoffs
- HCM diagnostic thresholds
- Athlete's heart differentiation criteria
- Longitudinal change significance thresholds

Economic and Healthcare System Impact

Cost-Benefit Analysis

Current System Costs:

- Manual segmentation time: 10-15 minutes per study × ~\$100/hour radiologist time = \$16-25 per study
- Repeat studies due to ambiguous findings: 5-10% of cases × \$1,500 per CMR = \$75-150 per original study
- Misdiagnosis costs: Delayed treatment, unnecessary restrictions, psychological impact
- Research inefficiency: Poor reproducibility increases required sample sizes by 40-60%

Unified Approach Benefits:

- Automated segmentation: <30 seconds, minimal expert review (1-2 min) = \$3-5 per study
- Reduced repeat imaging: Better reproducibility = fewer confirmatory studies
- Improved diagnostic accuracy: Earlier appropriate treatment, reduced false positives
- Research efficiency: Better reproducibility reduces required sample sizes, accelerates drug development

Conservative Estimate: \$50-100 saved per study, with 500,000+ cardiac MRIs performed annually in US alone = **\$25-50M annual savings** in US healthcare system, plus immeasurable benefits from improved diagnostic accuracy.

Global Standardization

One of the most significant but often overlooked benefits: the unified approach enables true international standardization. Currently:

- Different centers use different conventions
- Guidelines disagree across societies
- Multi-center trials struggle with measurement harmonization
- Population studies can't be directly compared

Unified total myocardial mass provides an anatomically-grounded, universally applicable standard. Research conducted in Asia, Europe, and North America becomes directly comparable. Drug trials can combine data across continents. Precision medicine initiatives can leverage global datasets.

Conclusion: The Time for Change Is Now

The case for unified total myocardial mass measurement is overwhelming:

Scientific: Anatomically accurate, biologically principled, eliminates artificial distinctions in continuous tissue

Technical: Improves AI segmentation performance (Dice 0.62→0.94), dramatically enhances reproducibility (ICC 0.44→>0.90), simplifies ground truth development

Clinical: Maintains all current diagnostic capabilities while improving accuracy in critical scenarios (HCM vs athlete's heart, LVH detection), eliminates 20-40g systematic bias, enables detection of papillary/trabecular pathology

Practical: Reduces annotation time by 50-70%, enables efficient AI model training, facilitates automated clinical workflows, decreases costs

Ethical: Provides patients with accurate diagnoses based on actual anatomy rather than historical compromises, aligns measurement methodology with medical reality

The current convention—excluding papillary muscles and trabeculations from myocardial mass—is a historical artifact perpetuated by inertia, not evidence. It was a reasonable compromise in the 2D echocardiography era but has become an impediment to progress in the age of high-resolution cardiac MRI and artificial intelligence.

We've reached a critical inflection point. The technology exists. The evidence is clear. The methodology is straightforward. What's needed now is collective will to update our practices to reflect anatomical reality.

The unified approach isn't radical innovation—it's fundamental honesty. It's measuring what's actually there instead of what's convenient to measure. It's asking AI to distinguish myocardium from blood (clear boundaries) rather than myocardium from myocardium (impossible distinctions).

For clinicians facing diagnostic dilemmas—the athlete with borderline hypertrophy, the patient with ambiguous LVH, the individual with possible non-compaction—accurate myocardial mass measurement can be the difference between correct diagnosis and clinical error. For researchers developing new therapies, reproducible measurements can be the difference between successful trials and failed studies. For healthcare systems, efficient automated analysis can be the difference between sustainable imaging programs and unsustainable costs.

The path forward is clear. The benefits are substantial. The time to act is now.

It's time to include what belongs in myocardial mass: all the myocardium.

References and Further Reading

This article synthesizes evidence from multiple domains:

- Cardiac MRI segmentation methodology
- Observer variability studies in medical imaging
- Clinical outcome studies (Framingham, UK Biobank)
- Deep learning approaches to medical image analysis
- Clinical guidelines from SCMR, ACC, AHA, ESC
- Pathophysiology of hypertrophic cardiomyopathy and athlete's heart

Key datasets mentioned:

- UK Biobank Cardiac MRI (40,000+ subjects)
- ACDC Challenge (automated cardiac diagnosis)
- M&Ms Challenge (multi-center, multi-vendor)

- Framingham Heart Study (1,424 patients)

For implementation details, consult:

- nnU-Net framework documentation
- MONAI (Medical Open Network for AI)
- PyTorch/TensorFlow medical imaging libraries
- DICOM segmentation standards